IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) - Cheng, A-L; Qin, S; Ikeda, M (Annals of Oncology, 2019)
et al.